jRCT1013240081招募中不适用
Safety and Efficacy of Axicabtagene Ciloleucel in Relapsed/Refractory Large B Cell Lymphoma (Axi-Cel.24)
Gilead Sciences (Kite Pharma)0 个研究点开始时间: 2024年12月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 主要终点
- Response rate at 6 months after axi-cel administration
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) 18 years of age or older at the time of enrollment
- •(2) Patients who meet the indications specified in Guidelines for the Promotion of Optimal Use, axicabtagene ciloleucel (Ref. 1).
- •(3) Patents who are scheduled to receive axi-cel at the participating medical institutions in this study (prospective observational study)
- •(4) Patients who have already received axi-cel administration at a medical institution participating in this study* (retrospective observational study)
- •(5) Patients who have given their free and voluntary consent to participate in this study or patients who do not refuse to participate in the study.
排除标准
- •Patients deemed inappropriate as study subjects by the principal investigator in participating medical institution (hereafter referred to as the "site principal investigator"
结局指标
主要结局
Response rate at 6 months after axi-cel administration
时间窗: 6 months
overall response, complete response, partial response
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different types of formulationsVasomotor symptoms as a sex hormone-dependent disorder in women and menMedDRA version: 20.0Level: LLTClassification code: 10067819Term: Andropausal symptoms Class: 10014698MedDRA version: 21.0Level: LLTClassification code: 10020407Term: Hot flashes Class: 10047065MedDRA version: 21.1Level: PTClassification code: 10027304Term: Menopausal symptoms Class: 100000004872CTIS2023-503968-16-00Bayer Consumer Care AG16
进行中（未招募）
1 期
Study evaluating the Safety and Efficacy of ABBV-383 in Subjects with Light Chain Amyloidosisight Chain AmyloidosisMedDRA version: 20.0Level: PTClassification code: 10002022Term: Amyloidosis Class: 100000004870CTIS2023-503429-20-00Abbvie Deutschland GmbH & Co. KG52
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteersPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA)age= 75 yearshypertensionsymptomatic heart failure (NYHA Class = II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.MedDRA version: 21.1Level: PTClassification code: 10051055Term: Deep vein thrombosis Class: 100000004866MedDRA version: 23.1Level: LLTClassification code: 10084868Term: Systemic embolism Class: 100000004848MedDRA version: 20.0Level: LLTClassification code: 10014521Term: Embolism pulmonary Class: 10038738diabetes mellitusCTIS2024-511526-31-00Celon Pharma S.A.38
招募中
1 期
A double-blind, placebo-controlled, randomised phase 1/2a study to evaluate the safety, tolerability and pharmacokinetics of single and repeated subcutaneous ascending-doses of DX243 in healthy volunteers followed by an extension to assess 1-month safety and preliminary efficacy in patients with mild age-related hearing loss.Age related hearing lossCTIS2023-505778-14-00Dendrogenix128
进行中（未招募）
1 期
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indicationslocally advanced or metastatic solid tumorsMedDRA version: 20.0Level: LLTClassification code: 10028982Term: Neoplasm biliary tract Class: 10029104MedDRA version: 26.1Level: PTClassification code: 10060121Term: Squamous cell carcinoma of head and neck Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104MedDRA version: 25.1Level: PTClassification code: 10061534Term: Oesophageal squamous cell carcinoma Class: 100000004864MedDRA version: 24.0Level: PTClassification code: 10085481Term: Hormone receptor positive HER2 negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073071Term: Hepatocellular carcinoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10056065Term: Oesophageal squamous cell carcinoma stage unspecified Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10051971Term: Pancreatic adenocarcinoma Class: 10029104CTIS2023-506227-29-00AbbVie Deutschland GmbH & Co. KG220